Vendor Intelligence Report: Hangzhou Youngpeptide Biotechnology HYB

Executive summary

HYB is a high-variance vendor file, not a simple pass/fail story. Across 21 Finnrick lab tests the record is 14 pass / 7 fail, for an overall pass rate of 67%. The catalog signal is uneven: GHK-Cu is the clear bright spot, while Retatrutide and Tirzepatide are materially weaker and need to be read against HYB’s external incident history, not averaged into a vendor-wide score. The product read also shifts under stricter grading, making exact-batch verification more important than brand-level reputation.

The most serious non-Finnrick finding is the blue-cap R10 Retatrutide file: community reports described emergency care after use, and an AFI result found zero detectable Retatrutide in the submitted vial while the public record still did not identify the compound. A separate Tirzepatide/Adipotide substitution trail and Yura’s HGH raw-material purity admission point to supplier-control risk rather than a one-off labeling annoyance.

HYB’s storefront is live and polished, but ownership and channel control are thinner: the strongest public anchor is a Yura-centered forum and messaging trail, with a later Alex/AlexDavis43 contact, not a registry-backed company file. The report follows the hybpeptides.com infrastructure migration, crypto-focused payment page, direct-contact bank-transfer return, Janoshik testing claims that were not public-search verifiable, and a reputation trail spanning Trustpilot, GLP-1 Forum, MESO-Rx, and Peppys routing.

Inside the full report:

• Appendix A Finnrick per-product pass/fail rates and methodology-divergence charts for all 3 tested products
• Dated R10, T60, H36, and HGH incident timeline with AFI, forum, and vendor-statement artifacts
• Operator and channel map covering Yura, AlexDavis43, Peppys access, storefront emails, and registry negatives
• Infrastructure and payment review of hybpeptides.com, Hostinger/DNS-PARKING migration, crypto tutorials, and direct bank transfers
• Janoshik-claim and batch-traceability analysis, including public-search negative findings
• Reputation and promotion scan across Trustpilot, MESO-Rx, GLP-1 Forum, X, coupon sites, Reddit, and Peppys invite routing

Risk assessment

• Retatrutide R10 and current Retatrutide buyer-safety risk — high: AFI reported zero Retatrutide in HYB R10 after reported hospitalizations, the unknown compound remains unidentified publicly, and Finnrick’s Retatrutide record is 9 tests, 5 pass / 4 fail, 71.16%.
• Tirzepatide substitution and mixed-test risk — high: HYB T60 Tirzepatide was reported to contain Adipotide instead of Tirzepatide, and Finnrick’s Tirzepatide record is 8 tests, 5 pass / 3 fail, 74.33%.
• HGH raw-material and H36 quality risk — high: HYB recalled H36 after the R10 supplier episode, a user alleged weak HGH 24, and Yura stated current HGH raw materials were below 90% purity before production resumed.
• Fulfillment and payment-loss risk — high: Trustpilot and MESO-Rx records describe Bitcoin/wire or direct-payment non-delivery, ghosting, stalled tracking, and customs/inspection delays despite continued vendor activity.
• Batch traceability and public COA-verification risk — medium: HYB claims Janoshik testing before bottling and batch-numbered reports, but public Janoshik search showed no HYB entries and older community records flagged unnumbered COAs.
• Corporate and channel-authentication risk — medium: No matching registry record or physical address was verified, Peppys access is gated, hyb.vip is not confirmed as a peptide storefront, and HYB provides no public authorized-channel or anti-counterfeit list.